Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.

Date publication

novembre 2015

Journal

The Lancet. Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr VERNEREY Dewi

Tous les auteurs :
Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P, Lledo G, Viret F, Ramée JF, Tubiana-Mathieu N, Dauba J, Dupuis O, Rinaldi Y, Mabro M, Aucoin N, Latreille J, Bonnetain F, Louvet C, Larsen AK, André T, de Gramont A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26474518

Résumé

The combination of an anti-VEGF or an anti-EGFR-targeted monoclonal antibody with chemotherapy has shown clinical activity in patients with metastatic colorectal cancer. However, combining both anti-VEGF and anti-EGFR antibodies with chemotherapy in first-line treatment resulted in adverse outcomes. We assessed whether the combination of erlotinib, an EGFR tyrosine kinase inhibitor, with bevacizumab could increase the efficacy of maintenance therapy in patients with unresectable metastatic colorectal cancer.

Mots clés

Aged, Angiogenesis Inhibitors, administration & dosage, Antineoplastic Agents, administration & dosage, Bevacizumab, administration & dosage, Colorectal Neoplasms, drug therapy, Disease-Free Survival, Drug Therapy, Combination, Erlotinib Hydrochloride, administration & dosage, Female, Humans, Maintenance Chemotherapy, Male, Middle Aged

Référence

Lancet Oncol.. 2015 Nov;16(15):1493-1505